Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy
Anagha Nadkarni,1 Iftekhar Kalsekar,1 Min You,1 Robert Forbes,2 Tony Hebden1
1Bristol-Myers Squibb, Plainsboro, NJ, USA; 2Otsuka Pharmaceutical Development and Commercialization, Princeton, NJ, USA
Objective: To compare total medical costs and utilization over a 12-month period in commercially insured patients receiving FDA-approved adjunctive atypical antipsychotics (aripiprazole, olanzapine, or quetiapine) for depression.
Methods: A retrospective claims analysis was conducted from 2005–2010 using the PharMetrics database. Subjects were adult commercial health-plan members with depression, identified using International Classification of Diseases codes and followed for 12 months after augmentation with an atypical antipsychotic. Outcomes included total medical costs, hospitalization, and ER visits. Generalized linear models and logistic regression were used to compare the total medical costs and the odds of hospitalization and ER visits between the treatment groups after adjusting for baseline demographic and clinical characteristics.
Results: A total of 9675 patients with depression were included in the analysis, of which 68.4% were female, with a mean age of 45.2 (±12.0) years. Adjusted 12-month total medical costs were higher for olanzapine ($14,275) and quetiapine ($12,998) compared to aripiprazole ($9,801; P < 0.05 for all comparisons with aripiprazole). When divided into inpatient and outpatient costs, olanzapine and quetiapine had significantly higher adjusted inpatient costs compared to aripiprazole ($6,124 and $4,538 vs $2,976, respectively; P < 0.05 for all comparisons with aripiprazole). Similar results were seen for adjusted outpatient costs. Adjusted odds of hospitalization for olanzapine (odds ratio [OR] = 1.73; 95% CI confidence interval [CI] = 1.42–2.10) and quetiapine (OR = 1.40; 95% CI = 1.21–1.60) were significantly higher than aripiprazole at 12 months. The adjusted odds of an ER visit for olanzapine (OR = 1.40; 95% CI = 1.18–1.65) and quetiapine (OR = 1.62; 95% CI = 1.44–1.81) were also significantly higher compared to aripiprazole at 12 months.
Conclusions: In commercially insured major depressive disorder patients, olanzapine and quetiapine were associated with higher total medical costs, the difference being primarily attributable to higher inpatient costs. Additionally, olanzapine and quetiapine were associated with significantly higher odds of hospitalization and ER visits compared to aripiprazole.
Keywords: depression, atypical antipsychotics, adjunctive therapy
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E
Published Date: 14 May 2013
Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy
Mody R, Eisenberg D, Hou L, Kamat S, Singer J, Gerson LB
Published Date: 22 April 2013
Neff GW, Kemmer N, Duncan C, Alsina A
Published Date: 12 April 2013
Duan Y, Zhao X, Ren W, Wang X, Yu KF, Li D, Zhang X, Zhang Q
Published Date: 14 March 2013
The role and uptake of private health insurance in different health care systems: are there lessons for developing countries?
Odeyemi IA, Nixon J
Published Date: 5 March 2013
Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States
Khorana AA, Dalal MR, Lin J, Connolly GC
Published Date: 13 February 2013
Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
Thorlund K, Druyts E, El Khoury AC, Mills EJ
Published Date: 16 November 2012
Cost of human immunodeficiency virus infection in Italy, 2007–2009: effective and expensive, are the new drugs worthwhile?
Rizzardini G, Restelli U, Bonfanti P, Porazzi E, Ricci E, Foglia E, Carenzi L, Croce D
Published Date: 5 September 2012
Cost-effectiveness of entecavir versus adefovir for the treatment of chronic hepatitis B in patients with decompensated cirrhosis from a third-party US payer perspective
Tsai N, Jeffers L, Cragin L, Sorensen S, Su W, Rosenblatt L, Tang H, Hebden T, Juday T
Published Date: 23 August 2012
New strategies for lowering the costs of antiretroviral treatment and care for people with HIV/AIDS in the United Kingdom
Gazzard B, Moecklinghoff C, Hill A
Published Date: 12 July 2012